Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 9/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4349912 | 0.95 | CHRM3 (0.45) | PDE4BCHRM3CHRM2CHRM1 | |
| SCHEMBL4364357 | 0.94 | PDE4B (0.44) | PDE4BCHRM3CHRM2CHRM1 | |
| SCHEMBL4348654 | 0.93 | PDE4B (0.43) | PDE4BCHRM3CHRM2CHRM1 | |
| SCHEMBL1364894 | 0.93 | CHRM3 (0.49) | PDE4BCHRM3CHRM2CHRM1 | |
| SCHEMBL4347608 | 0.93 | PDE4B (0.43) | PDE4BCHRM3CHRM2CHRM1WDR5 | |
| SCHEMBL4346099 | 0.92 | CHRM3 (0.45) | PDE4BCHRM3CHRM2CHRM1 | |
| SCHEMBL4350319 | 0.91 | PDE4B (0.45) | PDE4BCHRM3CHRM2CHRM1 | |
| SCHEMBL4348673 | 0.91 | PDE4B (0.42) | PDE4BCHRM3CHRM2CHRM1 | |
| SCHEMBL4352274 | 0.91 | PDE4B (0.44) | PDE4BCHRM3CHRM2CHRM1 | |
| SCHEMBL4362683 | 0.91 | CHRM3 (0.45) | PDE4BCHRM3CHRM2CHRM1WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071588-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | claimed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | claimed |
| US-8071588-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203677-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE4B, PDE1A | PDE4B 2/4885CHRM3 20/4885CHRM2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.